<unk>  (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors. It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma. In 2007 preliminary results were released from the Phase II clinical trial of intravenous<unk>  in combination with carboplatin and paclitaxel for relapsed ovarian cancer. Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.<unk>  has been granted orphan drug and fast track designation by the FDA, and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014. It is not approved in Europe . The approved pharmaceutical formulation is given intravenously.<unk>  is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele.
Belinostat
Nusinersen
Sotorasib
Inotersen
Beraprost
Carbidopa/levodopa
Umbralisib
Tezacaftor